Reyon Pharmaceutical Co Ltd
102460
Company Profile
Business description
Reyon Pharmaceutical Co Ltd is a Korea-based pharmaceutical company. It is engaged in the manufacturing and distribution of specialty medicines and raw materials. The main business of the company has been divided into generic drugs, original drugs, and drug substances The key products include eye drops, injection, antibiotics, skeletal muscle relaxants, coagulation drugs, anti-inflammatory enzymes, and blood vessels dialectic drugs, among others.
Contact
416, Yeongdong-daero
8th floor, Gangnam-gu
Seoul
KORT: +82 234075222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
449
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.40 | 22.00 | -0.24% |
| CAC 40 | 7,850.43 | 106.02 | 1.37% |
| DAX 40 | 24,240.82 | 198.92 | 0.83% |
| Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
| FTSE 100 | 9,061.49 | 37.68 | 0.42% |
| HKSE | 25,621.79 | 83.72 | 0.33% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,881.24 | 709.92 | 1.72% |
| NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
| S&P 500 | 6,358.91 | 49.29 | 0.78% |
| S&P/ASX 200 | 8,709.60 | 27.60 | -0.32% |
| SSE Composite Index | 3,593.84 | 11.54 | 0.32% |